Literature DB >> 3118799

Synergism between 9-deazainosine and DL-alpha-difluoromethylornithine in treatment of experimental African trypanosomiasis.

C J Bacchi1, R L Berens, H C Nathan, R S Klein, I A Elegbe, K V Rao, P P McCann, J J Marr.   

Abstract

Kinetoplastid hemoflagellates are sensitive to growth inhibition by various purine analogs. In this study the activities of 9-deazainosine (9-DINO), formycin B, and sinefungin were compared in experimental murine Trypanosoma brucei subsp. brucei infections, both singly and in combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO, eflornithine). Used singly, all of the purine analogs were able to suppress an acute T. brucei subsp. brucei infection. 9-DINO and formycin B were the most active. None of the purine analogs was curative when used singly against a strain causing chronic central nervous system infection. 9-DINO was highly effective when used in combination with DFMO in curing this central nervous system infection and another more stringent experimental infection. Neither sinefungin nor formycin B was active in combination with DFMO in curing the central nervous system experimental infection. 9-DINO was metabolized to phosphorylated derivatives of 9-deazaadenosine and 9-deazaguanosine by bloodstream trypomastigotes, but not by murine erythrocyte suspensions or kidney or liver homogenates--a potential rationale for the selectivity of the analog. These studies indicate that 9-DINO is a potent, nontoxic purine analog which, in combination with DFMO, is capable of late-stage cures of African trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118799      PMCID: PMC174951          DOI: 10.1128/AAC.31.9.1406

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy.

Authors:  F W Jennings; D D Whitelaw; G M Urquhart
Journal:  Parasitology       Date:  1977-10       Impact factor: 3.234

2.  The metabolism and cytotoxic effects of Formycin B in Trypanosoma cruzi.

Authors:  P Rainey; C E Garrett; D V Santi
Journal:  Biochem Pharmacol       Date:  1983-02-15       Impact factor: 5.858

3.  A comparison of the distribution and electron acceptor specificities of xanthine oxidase and aldehyde oxidase.

Authors:  T A Krenitsky; J V Tuttle; E L Cattau; P Wang
Journal:  Comp Biochem Physiol B       Date:  1974-12-15

4.  Phosphorylation and anti-leishmanial activity of formycin B.

Authors:  D A Carson; K P Chang
Journal:  Biochem Biophys Res Commun       Date:  1981-06-16       Impact factor: 3.575

5.  Problems of pharmacokinetic studies on alpha-difluoromethylornithine in mice.

Authors:  J C Romijn; C F Verkoelen; T A Splinter
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin.

Authors:  A B Clarkson; E J Bienen; C J Bacchi; P P McCann; H C Nathan; S H Hutner; A Sjoerdsma
Journal:  Am J Trop Med Hyg       Date:  1984-11       Impact factor: 2.345

7.  Aldehyde oxidase from rabbit liver: specificity toward purines and their analogs.

Authors:  W W Hall; T A Krenitsky
Journal:  Arch Biochem Biophys       Date:  1986-11-15       Impact factor: 4.013

8.  Activity of purine analogs against Leishmania tropica within human macrophages in vitro.

Authors:  J D Berman; L S Lee; R K Robins; G R Revankar
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis.

Authors:  A J Bitonti; C J Bacchi; P P McCann; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1985-05-15       Impact factor: 5.858

10.  Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial.

Authors:  S Van Nieuwenhove; P J Schechter; J Declercq; G Boné; J Burke; A Sjoerdsma
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

View more
  5 in total

1.  Inhibition of SET Domain-Containing Lysine Methyltransferase 7/9 Ameliorates Renal Fibrosis.

Authors:  Kensuke Sasaki; Shigehiro Doi; Ayumu Nakashima; Taisuke Irifuku; Kyoko Yamada; Keiko Kokoroishi; Toshinori Ueno; Toshiki Doi; Eisuke Hida; Koji Arihiro; Nobuoki Kohno; Takao Masaki
Journal:  J Am Soc Nephrol       Date:  2015-06-04       Impact factor: 10.121

2.  Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-alpha-difluoromethylornithine and standard trypanocides.

Authors:  C J Bacchi; H C Nathan; N Yarlett; B Goldberg; P P McCann; A Sjoerdsma; M Saric; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 3.  Eflornithine. A new drug in the treatment of sleeping sickness.

Authors:  I Van Bogaert; A Haemers
Journal:  Pharm Weekbl Sci       Date:  1989-06-23

4.  Antitrypanosomal activity of a new triazine derivative, SIPI 1029, In vitro and in model infections.

Authors:  C J Bacchi; M Vargas; D Rattendi; B Goldberg; W Zhou
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

5.  Fate of soluble methionine in African trypanosomes: effects of metabolic inhibitors.

Authors:  C J Bacchi; B Goldberg; J Garofalo-Hannan; D Rattendi; P Lyte; N Yarlett
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.